Base de dados : LILACS
Pesquisa : C04.557.337.428.080.125 [Categoria DeCS]
Referências encontradas : 143 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 15 ir para página                         

  1 / 143 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Rego, Eduardo Magalhäes
Texto completo
Texto completo
Id: biblio-898932
Autor: Furtado, Felipe Magalhães; Scheucher, Priscila Santos; Santana, Bárbara Amélia; Zanette, Dalila Lucíola; Calado, Rodrigo do Tocantins; Rego, Eduardo Magalhães; Matos, Daniel Mazza; Falcão, Roberto Passetto.
Título: Comparison of microRNA expression in high-count monoclonal B-cell lymphocytosis and Binet A chronic lymphocytic leukemia
Fonte: Rev. bras. hematol. hemoter;39(3):237-243, July-Sept. 2017. tab, graf.
Idioma: en.
Projeto: Conselho Nacional de Desenvolvimento Cientifico e Tecnologico.
Resumo: Abstract Background Evidence suggests that monoclonal B-cell lymphocytosis precedes all chronic lymphocytic leukemia cases, although the molecular mechanisms responsible for disease progression are not understood. Aberrant miRNA expression may contribute to the pathogenesis of chronic lymphocytic leukemia. The objective of this study was to compare miRNA expression profiles of patients with Binet A chronic lymphocytic leukemia with those of subjects with high-count monoclonal B-cell lymphocytosis and healthy volunteers (controls). Methods Twenty-one chronic lymphocytic leukemia patients, 12 subjects with monoclonal B-cell lymphocytosis and ten healthy volunteers were enrolled in this study. Flow cytometry CD19+CD5+-based cell sorting was performed for the chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis groups and CD19+ cells were sorted to analyze the control group. The expressions of miRNAs (miR-15a, miR-16-1, miR-29b, miR-34a, miR-181a, miR-181b and miR-155) were determined by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). Results Significant differences between the expressions in the chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis groups were restricted to the expression of miR-155, which was higher in the former group. A comparison between healthy controls and monoclonal B-cell lymphocytosis/chronic lymphocytic leukemia patients revealed higher miR-155 and miR-34a levels and lower miR-15a, miR-16-1, miR-181a and miR-181b in the latter group. Conclusions Our results show a progressive increase of miR-155 expression from controls to monoclonal B-cell lymphocytosis to chronic lymphocytic leukemia. The role of miR-155 in the development of overt chronic lymphocytic leukemia in individuals with monoclonal B-cell lymphocytosis must be further analyzed.
Descritores: Teste de Stanford-Binet
Linfócitos B
Leucemia Linfocítica Crônica de Células B
MicroRNAs
Linfocitose
Limites: Seres Humanos
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM


  2 / 143 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: lil-640876
Autor: Santos, Iris Mattos; Franzon, Carine Muniz Ribeiro; Koga, Adolfo Haruo.
Título: Laboratory diagnosis of chronic myelomonocytic leukemia and progression to acute leukemia in association with chronic lymphocytic leukemia: morphological features and immunophenotypic profile
Fonte: Rev. bras. hematol. hemoter;34(3):242-244, 2012. ilus.
Idioma: en.
Resumo: Chronic myelomonocytic leukemia is a clonal stem cell disorder that is characterized mainly by absolute peripheral monocytosis. This disease can present myeloproliferative and myelodysplastic characteristics. According to the classification established by the World Health Organization, chronic myelomonocytic leukemia is inserted in a group of myeloproliferative/myelodysplastic disorders; its diagnosis requires the presence of persistent monocytosis and dysplasia involving one or more myeloid cell lineages. Furthermore, there should be an absence of the Philadelphia chromosome and the BCR/ABL fusion gene and less than 20% blasts in the blood or bone marrow. Phenotypically, the cells in chronic myelomonocytic leukemia can present myelomonocytic antigens, such as CD33 and CD13, overexpressions of CD56 and CD2 and variable expressions of HLA-DR, CD36, CD14, CD15, CD68 and CD64. The increase in the CD34 expression may be associated with a transformation into acute leukemia. Cytogenetic alterations are frequent in chronic myelomonocytic leukemia, and molecular mutations such as NRAS have been identified. The present article reports on a case of chronic myelomonocytic leukemia, diagnosed by morphologic and phenotypical findings that, despite having been suggestive of acute monocytic leukemia, were differentiated through a detailed analysis of cell morphology. Furthermore, typical cells of chronic lymphocytic leukemia were found, making this a rare finding.
Descritores: Leucemia Linfocítica Crônica de Células B
Leucemia Mielomonocítica Aguda
Leucemia Mielomonocítica Crônica
Limites: Seres Humanos
Idoso
Tipo de Publ: Relatos de Casos
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM


  3 / 143 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1020995
Autor: Rogers, Thomas S; Gardner, Juli-Anne; Devitt, Katherine A.
Título: High-grade B-Cell lymphoma with MYC and BCL6 rearrangements associated with Richter transformation of chronic lymphocytic leukemia
Fonte: Autops. Case Rep;9(3):e2019090, July-Sept. 2019. ilus, graf.
Idioma: en.
Resumo: Richter transformation (RT), or Richter syndrome, is defined as the transformation of chronic lymphocytic leukemia (CLL) to an aggressive B-cell lymphoma. The vast majority, up to 99%, transform into diffuse large B-cell lymphoma (DLBCL), with a small subset (<1%) becoming classical Hodgkin lymphoma. Approximately half of RT cases progress through a pathway involving dysregulation of C-MYC. High-grade B-cell lymphoma (HGBL) is a recent diagnostic category of aggressive B-cell lymphomas set forth in the updated 2017 WHO Classification of Hematopoietic and Lymphoid Tissues. HGBL with MYC and BCL2 and/or BCL6 rearrangements, formerly "double-hit" and "triple-hit" lymphomas, comprise the majority of HGBL cases. Patients with HGBL have a worse prognosis than those with diffuse large B-cell lymphoma. We present a case of RT with rearrangements of MYC and BCL6. To our knowledge, there are no reported cases of RT with a "double-hit" lymphoma genotype.
Descritores: Linfoma Difuso de Grandes Células B/patologia
-Linfoma não Hodgkin
Leucemia Linfocítica Crônica de Células B
Citogenética
Limites: Seres Humanos
Masculino
Meia-Idade
Tipo de Publ: Relatos de Casos
Conferência Clínica
Responsável: BR26.7 - Serviço de Biblioteca e Documentação Científica


  4 / 143 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Cuba
Texto completo
Texto completo
Id: biblio-960440
Autor: Duque Estrada, Lidia; Betancourt Reyes, Gilberto Lázaro; Betancourt Betancourt, Gilberto de Jesús; Junco Bonet, Miguel Damián.
Título: Leucemia linfocítica crónica con infiltración ocular / Chronic lymphocytic leukemia with eye infiltration
Fonte: Rev. cuba. hematol. inmunol. hemoter;33(4):85-91, oct.-dic. 2017. ilus.
Idioma: es.
Resumo: La incidencia de la leucemia linfocítica crónica (LLC) aumenta progresivamente con la edad; aproximadamente el 75 por ciento de los casos presentan 60 años o más. Este tipo de leucemia es más frecuente en varones y se desconoce su causa, existen casos que son de origen hereditario. Se presenta el caso de un paciente con el diagnóstico de LLC con infiltración ocular. Paciente blanco, masculino de 76 años de edad con antecedentes de salud de haber sido diagnosticado con LLC desde hace 5 años que se trata con Leukeran (Clorambucil) (2mg) 2 tabletas en el almuerzo y 3 tab en la comida, así como de prednisona (5mg) 1 cada 8 horas solo cuando está descompensado. Hace alrededor de 3 días comenzó con astenia, anorexia, mareos, dolor e inflamación del párpado superior derecho. El examen físico, la biopsia del párpado superior y el frotis de sangre revelaron la presencia de una recaída hematológica de la LLC con infiltración ocular(AU)

The incidence of chronic lymphocytic leukemia (CLL) increases progressively with age, approximately 75 percent of cases present 60 years or more. This type of leukemia is more frequent in men and its cause is unknown, there are cases that are of hereditary origin. A clinical case of a patient with the diagnosis of Chronic Lymphocytic Leukemia with ocular infiltration is presented. A 76-year-old white male patient with a health history of having been diagnosed with a Chronic Lymphocytic Leukemia for 5 years who is treated with Leukeran (Chlorambucil) ( 2mg) 2 tab at lunch and 3 at night; and prednisone (5mg) 1 tab every 8 hours. About 3 days ago begins with asthenia, anorexia, dizziness, pain and swelling of the upper right eyelid. Physical examination, upper eyelid biopsy and blood smears reveal the presence of a hematological relapse with ocular infiltration(AU)
Descritores: Leucemia Linfocítica Crônica de Células B/complicações
Leucemia Linfocítica Crônica de Células B/epidemiologia
Manifestações Oculares
-Doenças Palpebrais/complicações
Limites: Seres Humanos
Masculino
Idoso
Tipo de Publ: Relatos de Casos
Responsável: CU1.1 - Biblioteca Médica Nacional


  5 / 143 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1010189
Autor: Galvano, Camila; Dos Santos, Patricia; Stanganelli, Carmen; Slavutsky, Irma.
Título: Mutaciones del gen NOTCH1 en la leucemia linfocítica crónica / NOTCH1 gene mutations in chronic lymphocytic leukemia
Fonte: Salud(i)ciencia (Impresa) = Salud(i)ciencia (En linea);23(4):332-338, mar. 2019. tab, graf.
Idioma: es.
Resumo: Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. The disease has\r\na highly variable clinical course, ranging from very indolent cases to patients with aggressive and rapidly\r\nprogressing outcome. Genetic studies are useful tools in analyzing this pathology, and have been incorporated in international risk classifications. The analysis of genomic rearrangements and the mutational status of immunoglobulin heavy chain variable have allowed risk groups of high prognostic value to be established. More recently, next generation sequencing studies have identified novel somatic mutations that could explain the wide clinical variability of this pathology. Among them, the analysis of NOTCH1 (neurogenic locus notch homolog protein 1) gene mutations are of interest, as deregulation is associated with tumorigenesis. NOTCH11 mutations are mostly located at exon 34 (80% of cases) and 3´UTR (untranslated region). They produce premature stop codons that produce a constitutively active and stable NOTCH1 protein. NOTCH1 mutations are associated with adverse prognosis and refractoriness to treatment. The aim of this study was to analyze NOTCH1 mutations in CLL patients by ASO-PCR and sequencing. Our results found 4.4% of cases with NOTCH1 mutated values concordant with international observations (5%-10%). Including them in the genetic status of CLL patients allows the characterization of risk groups, an aspect of great importance in clinical practice and therapeutic decisions, to be refined.

La leucemia linfocítica crónica (LLC) es la leucemia más frecuente en adultos de Occidente. Presenta\r\nun curso clínico altamente variable, con pacientes que requieren tratamiento inmediato y otros con un curso indolente de la enfermedad. Los estudios genéticos constituyen herramientas de suma utilidad en esta enfermedad, encontrándose incorporados a las clasificaciones de riesgo internacionales. El análisis de los rearreglos genómicos y del estado mutacional de los genes IGHV (immunoglobulin heavy chain variable region) ha hecho factible establecer grupos de riesgo de alto valor pronóstico. Más recientemente, estudios de secuenciación de última generación permitieron la detección de mutaciones\r\nsomáticas previamente desconocidas en esta afección, que podrían explicar la amplia variabilidad clínica\r\nobservada en la LLC. Entre ellas, resultan de interés las observadas en el gen NOTCH1 (neurogenic locus notch homolog protein 1), cuya desregulación se asocia con el desarrollo tumoral. Estas mutaciones se acumulan en mayor medida en el exón 34 (80% de los casos) y en la región 3´UTR (untraslated region), lo que genera codones de terminación prematuros que originan una proteína NOTCH1 constitutivamente activa y más estable, los cuales se asocian con pronóstico adverso y refractariedad al tratamiento. Nuestro objetivo fue evaluar mutaciones de NOTCH1 en nuestros pacientes mediante ASO-PCR y secuenciación. Se detectaron mutaciones en el 4.4% de los casos, valor concordante con los datos internacionales (5% a 10%). Su inclusión en la caracterización genética de los pacientes con LLC permitirá refinar la categorización de los grupos de riesgo, aspecto de suma importancia tanto en el seguimiento clínico como en la toma de decisiones terapéuticas.
Descritores: Leucemia Linfocítica Crônica de Células B
Citogenética
Receptor Notch1
Mutação/genética
Limites: Seres Humanos
Tipo de Publ: Revisão
Responsável: AR392.1 - Biblioteca


  6 / 143 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: lil-764217
Autor: Matos, Daniel Mazza; Furtado, Felipe Magalhães; Falcão, Roberto Passetto.
Título: Monoclonal B-cell lymphocytosis in individuals from sporadic (non-familial) chronic lymphocytic leukemia families persists over time, but does not progress to chronic B-cell lymphoproliferative diseases
Fonte: Rev. bras. hematol. hemoter;37(5):292-295, Sept.-Oct. 2015. tab, graf.
Idioma: en.
Resumo: BACKGROUND: Monoclonal B-cell lymphocytosis is classified as 'high-count or clinical' monoclonal B-cell lymphocytosis and 'low-count or population' monoclonal B-cell lymphocytosis. Previously, 167 first-degree relatives pertaining to sporadic (non-familial) chronic lymphocytic leukemia families were studied and the presence of seven monoclonal B-cell lymphocytosis individuals was reported.OBJECTIVE: The aim of this report is to describe the outcomes of five of the original monoclonal B-cell lymphocytosis individuals.METHODS: Flow cytometry analysis was performed on mononuclear cells previously isolated from peripheral blood samples. A strategy of sequential gating designed to identify the population of CD19+/CD5+ B-lymphocytes was used and, subsequently, the monoclonal B-cell lymphocytosis cells were characterized by the CD20weak/CD79bweak/negative phenotype.RESULTS: The monoclonal B-cell lymphocytosis clone showed consistent stability over time with little variations in size. After a median follow-up of 7.6 years, none of the five monoclonal B-cell lymphocytosis individuals progressed to chronic lymphocytic leukemia or other B-cell lymphoproliferative disease.CONCLUSIONS: The data of this study suggest that chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis detected in the context of sporadic chronic lymphocytic leukemia families is not prone to clinical evolution and could be just a sign of immune senescence.
Descritores: Linfócitos B
Leucemia de Células B
Leucemia Linfocítica Crônica de Células B
Relações Familiares/etnologia
Citometria de Fluxo
Linfocitose
Transtornos Linfoproliferativos
Anticorpos Monoclonais
Limites: Seres Humanos
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM


  7 / 143 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: biblio-898923
Autor: Arlindo, Elissandra Machado; Marcondes, Natália Aydos; Fernandes, Flavo Beno; Faulhaber, Gustavo Adolpho Moreira.
Título: Quantitative flow cytometric evaluation of CD200, CD123, CD43 and CD52 as a tool for the differential diagnosis of mature B-cell neoplasms
Fonte: Rev. bras. hematol. hemoter;39(3):252-258, July-Sept. 2017. tab, graf.
Idioma: en.
Resumo: Abstract Background Distinction between mature B-cell neoplasms can be difficult due to overlapping of immunologic features and clinical manifestations. This study investigated whether quantifying mean fluorescence intensity of four monoclonal antibodies in a flow cytometry panel is useful for the differential diagnosis and characterization of these disorders. Methods The expressions of CD52, CD200, CD123 and CD43 were analyzed in samples from 124 patients with mature B-cell neoplasms. The quantitative estimation of these antigens was assessed by mean fluorescence intensity. Results The cases included were 78 chronic lymphocytic leukemias, three atypical chronic lymphocytic leukemias, six marginal zone lymphomas, 11 splenic marginal zone lymphomas, nine lymphoplasmacytic lymphomas, six mantle cell lymphomas, two hairy cell leukemias, two hairy cell leukemias variant, five follicular lymphomas, one Burkitt lymphoma and one diffuse large B-cell lymphoma. The mean fluorescence intensity of CD200 was higher in atypical chronic lymphocytic leukemia, chronic lymphocytic leukemia and hairy cell leukemia cases. CD123 showed higher mean fluorescence intensities in hairy cell leukemia cells. Chronic lymphocytic leukemia, atypical chronic lymphocytic leukemia and mantle cell lymphoma had higher expression of CD43 and all follicular lymphoma cases had very low mean fluorescence intensity values. CD52 expression was consistently positive among all cases. Conclusion Quantitative evaluation of these markers can be a useful additional tool to better identify some types of mature B-cell neoplasms.
Descritores: Linfócitos B
Leucemia Linfocítica Crônica de Células B
Imunofenotipagem
Linfoma de Células B
Citometria de Fluxo
Limites: Seres Humanos
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM


  8 / 143 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Chauffaille, Maria de Lourdes L. F
Texto completo
Texto completo
Id: biblio-898950
Autor: Zorovich, Maria Eduarda Sanseverino de Lourenço da Motta; Dourado, Denise Albuquerque; Chauffaille, Maria de Lourdes Lopes Ferrari.
Título: Chromosomal aberrations detected by Fluorescence in situ hybridization in 344 Brazilian chronic lymphocytic leukemia patients
Fonte: Rev. bras. hematol. hemoter;39(4):388-390, Oct.-Dec. 2017. tab.
Idioma: en.
Descritores: Leucemia Linfocítica Crônica de Células B
Aberrações Cromossômicas
Hibridização in Situ Fluorescente
Limites: Seres Humanos
Tipo de Publ: Carta
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM


  9 / 143 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Texto completo
Id: lil-449985
Autor: Chiattone, Carlos Sergio; Falcão, Roberto Passetto.
Título: Leucemia linfóide crônica: nova visão de uma velha doença (II Encontro Brasileiro de Consenso em LLC-B) / Chronic lymphocytic leukemia: a new vision of an old disease (II Brazilian Consensus Meeting on CLL-B)
Fonte: Rev. bras. hematol. hemoter;27(4):227-228, out.-dez. 2005.
Idioma: pt.
Descritores: Leucemia Linfocítica Crônica de Células B
Leucemia Linfoide
Limites: Seres Humanos
Tipo de Publ: Editorial
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM


  10 / 143 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Id: biblio-931296
Autor: Castro, Eric Delfraro.
Título: Expressão de proteínas envolvidas na apoptose e resistência às múltiplas drogas em células da leucenia linfóide crônica tratadas ou não com fludarabina.
Fonte: Rio de Janeiro; s.n; 2004. 127 p. ilus, tab, graf.
Idioma: pt.
Tese: Apresentada a Instituto Oswaldo Cruz para obtenção do grau de Mestre.
Resumo: A leucemia linfóide crônica de células B (LLC-B) caracteriza-se pelo acúmulo de linfócitos monoclonais do tipo B maduros que possuem uma sobrevida longa devido a alterações no mecanismo de apoptose. Algumas proteínas como a Bcl-2, a p53, a c-Myc, a glicoproteína-P e a mrp possuem um papel primordial nesse mecanismo, quando presentes ou alteradas, podendo promover resistência ao tratamento quimioterápico. O objetivo deste estudo foi analisar a expressão de diversas proteínas envolvidas com a apoptose e a resistência às drogas em células de pacientes portadores de LLC-B e correlacioná-las com o índice de apoptose induzida pela fludarabina e com fatores prognósticos já estabelecidos. As expressões das proteínas foram determinadas antes e após a incubação com fludarabina por 12 horas com anticorpos monoclonais, e o índice de apoptose com anexina V e iodeto de propídeo, ambos por citometria de fluxo. Linhagens celulares e linfócitos de indivíduos normais foram utilizados como controles. A expressão da p53 foi positiva em 28,6 por cento dos casos, sendo mais freqüente em pacientes previamente tratados em comparação com os não tratados (p. = 0,011). Ao contrário, as outras proteínas estudadas apresentaram uma elevada expressão: c-Myc (68,3 por cento), Bcl-2 (90 por cento), glicoproteína-P (65,1 por cento), mrp (66,1 por cento) sem relação com a presença ou não do tratamento prévio, ou com o estadiamento de Binet. O aumento na expressão da proteína p53, observado nas amostras de pacientes previamente tratados, ao contrário dos não-tratados, provavelmente está relacionado à evolução da doença e à aquisição de alterações do gene TP53 nesses pacientes. Reforçando esta observação, a expressão elevada da p53 apresentou uma correlação significativa com diversos fatores de mau prognóstico como a taxa diminuída de hemoglobina, a taxa aumentada de b2-microglobulina e com o TDL menor que 12 meses. A correlação encontrada entre a expressão da proteína p53 com a expressão da proteína mrp sugere, ainda, a possibilidade de que mutações no gene TP53 promovam um aumento na transcrição do promotor da mrp promovendo assim falha na resposta terapêutica com progressão da doença...
Descritores: Apoptose
Resistência a Múltiplos Medicamentos
Leucemia Linfocítica Crônica de Células B
Proteínas Oncogênicas
Limites: Seres Humanos
Responsável: BR15.1 - Biblioteca de Ciências Biomédicas
BR15.1 - Biblioteca de Ciências Biomédicas; BR440.1



página 1 de 15 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde